Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Acer Therapeutics Inc. | opxa_ex991.htm |
UNITED
STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d) of theSecurities Exchange Act of
1934
Date of Report (date of
earliest event reported): October 28, 2016
OPEXA THERAPEUTICS,
INC.
(Exact
name of registrant as specified in its charter)
|
Texas
|
|
001-33004
|
|
76-0333165
|
|
(State
or other jurisdiction ofincorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
2635 Technology Forest Blvd., The Woodlands, Texas
77381
(Address of
principal executive offices) (Zip
Code)
Registrant’s
telephone number, including area code: (281) 272-9331
N/A
(Former name or
former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item
7.01. Regulation FD Disclosure.
On
October 28, 2016, Opexa Therapeutics, Inc. (the “Company”)
announced the top-line results from its Phase 2b
“Abili-T” clinical trial designed to evaluate the
efficacy and safety of Tcelna (imilecleucel-T) in patients with
secondary progressive multiple sclerosis. Tcelna did not meet the
primary endpoint of reduction in brain volume change (atrophy), nor
did it meet the secondary endpoint of reduction of the rate of
sustained disease progression.
A copy
of the press release is furnished as Exhibit 99.1 and incorporated
herein by reference.
Item
9.01. Financial Statements and
Exhibits.
(d)
Exhibits.
|
Exhibit
No.
|
|
Description
|
|
|
Press release
issued by Opexa Therapeutics, Inc. on October 28,
2016.
|
The information in Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed “filed” for
the purposes of Section 18 of the Securities Exchange Act of 1934
or otherwise subject to the liabilities under that Section, nor be
deemed to be incorporated by reference into the filings of the
registrant under the Securities Act of 1933.
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
OPEXA THERAPEUTICS,
INC.
|
|
|
|
|
|
|
|
|
Dated: October 28,
2016
|
By:
|
/s/
Neil K.
Warma
|
|
|
|
|
Neil K. Warma |
|
|
|
|
President, Chief Executive Officer and Acting Chief Financial Officer |
|
3
EXHIBIT INDEX
|
Exhibit
No.
|
|
Description
|
|
|
Press release
issued by Opexa Therapeutics, Inc. on October 28,
2016.
|